In the current trial, two CSF presynaptic biomarkers (SNAP25 and SYT1) and one postsynaptic biomarker (NG) were included to examine the effects of p75NTR modulation on synaptic integrity in human AD. The gene discussed is SYT1; the disease is Alzheimer disease.